Association of apolipoprotein A1 -75 G/A polymorphism with susceptibility to the development of acute lung injury after cardiopulmonary bypass surgery

Lipids in Health and Disease

Fang He¹  Guofeng Liu¹  Dongke Liang¹  Beiwei Liang¹  Yanhua Chen¹  Bingdong Zhang¹  Jie Tu¹ 

[1] Institute of cardiovascular Diseases, The First Affiliated Hospital of Guangxi, Medical University, 6 ShuangYong Road, Nanning, Guangxi 530021, China

关键词: Gene polymorphism;    Cardiopulmonary bypass;    Acute lung injury;    Apolipoprotein A1;   

Others  :  829189
DOI  :  10.1186/1476-511X-12-172

 received in 2013-10-17, accepted in 2013-10-28,  发布年份 2013

【 摘 要 】

Introduction

Apolipoprotein A1 (apoA1) is the major apoprotein constituent of high density lipoprotein (HDL) which exerts innate protective effects in systemic inflammation. However, its role in the acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) has not been well studied. The objective of this study was to investigate the potential association between APOA1 -75 G/A polymorphism and the development of ALI after cardiopulmonary bypass (CPB) surgery.

Materials and methods

A hospital-based case–control study was conducted in patients with ALI (n = 300), patients without ALI (n = 300) and healthy controls (n = 300). Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) assay was applied to assess the APOA1 -75 G/A genotypes.

Results

Patients with ALI had a significantly higher frequency of APOA1 -75 AA genotype [odds ratio (OR) =1.75, 95% confidence interval (CI) = 1.04, 2.92; P = 0.03] than patients without ALI. APOA1 -75 AA genotype (OR =3.47, 95% CI = 1.60, 7.52; P = 0.002) and A allele (OR =1.92, 95% CI = 1.24, 2.96; P = 0.003) were the significant independent prognostic factors for the 30-day survival rate of patients with ALI after CPB surgery.

Conclusion

Our study suggested that APOA1 -75 AA genotype was associated with a higher ALI risk after CPB surgery. Patients with the APOA1 -75 AA genotype and A allele had higher 30-day mortality of ALI after CPB surgery. Additional studies are needed to confirm this finding.

【 授权许可】

   
2013 Tu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Hammermeister KE, Burchfiel C, Johnson R, Grover FL: Identification of patients at greatest risk for developing major complications at cardiac surgery. Circulation 1990, 82:IV380-IV389.
• [2]Wakayama F, Fukuda I, Suzuki Y, Kondo N: Neutrophil elastase inhibitor, sivelestat, attenuates acute lung injury after cardiopulmonary bypass in the rabbit endotoxemia model. Ann Thorac Surg 2007, 83:153-160.
• [3]Westaby S, Fleming J, Royston D: Acute lung injury during cardiopulmonary bypass, the role of neutrophil sequestration and lipid peroxidation. Trans Am Soc Artif Intern Organs 1985, 31:604-609.
• [4]Bando K, Pillai R, Cameron DE, Brawn JD, Winkelstein JA, Hutchins GM, Reitz BA, Baumgartner WA: Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990, 99:873-877.
• [5]Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM: Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg 1999, 68:1107-1115.
• [6]Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, Gimbrone MA Jr, Hoffman E, Hubmayr RD, et al.: Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2003, 167:1027-1035.
• [7]Albahrani AI, Usher JJ, Alkindi M, Marks E, Ranganath L, Al-yahyaee S: ApolipoproteinA1–75 G/A (M1-) polymorphism and lipoprotein(a); anti- vs. pro-Atherogenic properties. Lipids Health Dis 2007, 6:19. BioMed Central Full Text
• [8]Saha N, Tay JS, Low PS, Humphries SE: Guanidine to adenine (G/A) substitution in the promoter region of the apolipoprotein AI gene is associated with elevated serum apolipoprotein AI levels in Chinese non-smokers. Genet Epidemiol 1994, 11:255-264.
• [9]Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
• [10]Reddy AJ, Kleeberger SR: Genetic polymorphisms associated with acute lung injury. Pharmacogenomics 2009, 10:1527-1539.
• [11]Chen S, Xu L, Tang J: Association of interleukin 18 gene polymorphism with susceptibility to the development of acute lung injury after cardiopulmonary bypass surgery. Tissue Antigens 2010, 76:245-249.
• [12]Wang JF, Bian JJ, Wan XJ, Zhu KM, Sun ZZ, Lu AD: Association between inflammatory genetic polymorphism and acute lung injury after cardiac surgery with cardiopulmonary bypass. Med Sci Monit 2010, 16:CR260-CR265.
• [13]Liu Y, Shao Y, Yu B, Sun L, Lv F: Association of PBEF gene polymorphisms with acute lung injury, sepsis, and pneumonia in a northeastern Chinese population. Clin Chem Lab Med 2012, 50:1917-1922.
• [14]Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC: Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. Crit Care Med 2007, 35:1290-1295.
• [15]Tsangaris I, Tsantes A, Bonovas S, Lignos M, Kopterides P, Gialeraki A, Rapti E, Orfanos S, Dimopoulou I, Travlou A, Armaganidis A: The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS. Thromb Res 2009, 123:832-836.
• [16]Reddy AJ, Christie JD, Aplenc R, Fuchs B, Lanken PN, Kleeberger SR: Association of human NAD(P)H: quinone oxidoreductase 1 (NQO1) polymorphism with development of acute lung injury. J Cell Mol Med 2009, 13:1784-1791.
• [17]Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR: Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury. FASEB J 2007, 21:2237-2246.
• [18]Gao L, Grant A, Halder I, Brower R, Sevransky J, Maloney JP, Moss M, Shanholtz C, Yates CR, Meduri GU, et al.: Novel polymorphisms in the myosin light chain kinase gene confer risk for acute lung injury. Am J Respir Cell Mol Biol 2006, 34:487-495.
• [19]Toptas B, Gormus U, Ergen A, Gurkan H, Kelesoglu F, Darendeliler F, Bas F, Dalan AB, Izbirak G, Isbir T: Comparison of lipid profiles with APOA1 MspI polymorphism in obese children with hyperlipidemia. In Vivo 2011, 25:425-430.
• [20]Smach MA, Edziri H, Charfeddine B, Ben Othman L, Lammouchi T, Ltaief A, Nafati S, Dridi H, Bennamou S, Limem K: Polymorphism in apoA1 influences high-density lipoprotein cholesterol levels but is not a major risk factor of alzheimer’s disease. Dement Geriatr Cogn Dis Extra 2011, 1:249-257.
• [21]Padmaja N, Kumar MR, Adithan C: Association of polymorphisms in apolipoprotein A1 and apolipoprotein B genes with lipid profile in Tamilian population. Indian Heart J 2009, 61:51-54.
• [22]Souverein OW, Jukema JW, Boekholdt SM, Zwinderman AH, Tanck MW: Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD. Eur J Hum Genet 2005, 13:445-451.
• [23]Sorkin SC, Forestiero FJ, Hirata MH, Guzman EC, Cavalli SA, Bertolami MC, Salazar LA, Hirata RD: APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Clin Chem Lab Med 2005, 43:1339-1345.
• [24]Hamrita B, Ben Nasr H, Gabbouj S, Bouaouina N, Chouchane L, Chahed K: Apolipoprotein A1–75 G/A and +83 C/T polymorphisms: susceptibility and prognostic implications in breast cancer. Mol Biol Rep 2011, 38:1637-1643.
• [25]Dawar R, Gurtoo A, Singh R: Apolipoprotein A1 gene polymorphism (G-75A and C + 83 T) in patients with myocardial infarction: a pilot study in a north Indian population. Am J Clin Pathol 2010, 134:249-255.
• [26]Koutsis G, Panas M, Giogkaraki E, Karadima G, Sfagos C, Vassilopoulos D: An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis. Mult Scler 2009, 15:174-179.
• [27]Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, de Arruda Cardoso Smith M: Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med 2009, 9:319-325.
• [28]Dixit M, Choudhuri G, Saxena R, Mittal B: Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease. Can J Gastroenterol 2007, 21:569-575.
• [29]Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kolsch H: APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol 2005, 58:436-441.
• [30]Zou Y, Hu D, Yang X, Jia X, Wang L, Cui L, Liu X, Gao M, Wei Y, Xu Z: Relationships among apolipoprotein A1 gene polymorphisms, lipid levels and coronary atherosclerosis disease. Chin Med J (Engl) 2003, 116:665-668.